Several factors are associated with increased mortality in patients with bullous pemphigoid, with mortality rates increasing 5 years after diagnosis.

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition that leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

An sBLA seeking approval of Dupixent for treating bullous pemphigoid (“BP”) is currently under priority review in the United States. A decision from the FDA is expected on June 20, 2025.